Novo Nordisk Bets $256m On Mystery Molecule

The Danish group has licensed an unnamed product with an unknown mechanism.  

3d different tablets and pills on a white background with question marks

For any other company, spending €235m ($256m) on a preclinical program with an unproven mechanism might be a punchy move. But Novo Nordisk A/S has money to burn thanks to its wildly successful diabetes and obesity therapies, so taking a leap into the unknown is not as huge a risk as it might be.

Key Takeaways

  • Novo has licensed a preclinical obesity candidate from EraCal Therapeutics for €235m

The company has bought the rights to develop and sell an oral, small-molecule obesity asset developed by EraCal Therapeutics...

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.